MBRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Moleculin Biotech Inc (MBRX) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. The company shows no significant positive financial growth trends, lacks strong trading signals, and has limited catalysts to drive immediate or long-term price appreciation. Holding or exploring other opportunities may be more prudent.
The MACD is slightly positive at 0.0306 but contracting, indicating weakening momentum. RSI is neutral at 57.958, and moving averages are converging, showing no clear trend. The pre-market price is $2.52, down 0.79%, and the stock is trading near its pivot level of $2.527, suggesting limited immediate upside.
The acceptance of an abstract on its lead drug candidate, annamycin, for presentation at the 2026 ASCO Annual Meeting highlights potential scientific progress and cardiac safety at high doses.
Revenue and gross margin remain stagnant at $
No significant hedge fund or insider trading trends were observed.
In Q4 2025, revenue remained at $0 with no YoY growth. Net income dropped significantly to -$15.448 million (-350.49% YoY), and EPS fell to -6.9 (-122.56% YoY). Gross margin also showed no improvement, remaining at $0.
No analyst rating or price target changes were provided, and there is no data on Wall Street sentiment for this stock.
